Can You Take Sildenafil (Generic) with Rosuvastatin?

Pharmacokinetic Basis: Why These Drugs Don't Clash

Sildenafil and rosuvastatin travel through the body via almost entirely separate metabolic routes, which is why co-prescribing carries minimal pharmacokinetic risk.

Sildenafil undergoes extensive hepatic metabolism by cytochrome P450 3A4 (CYP3A4), with a minor contribution from CYP2C9 [1]. Its active metabolite, N-desmethyl sildenafil, accounts for roughly 20% of the parent compound's pharmacologic effect. The drug is neither a substrate nor an inhibitor of organic anion transporting polypeptides (OATP1B1 or OATP1B3) at clinically relevant plasma concentrations.

Rosuvastatin, by contrast, is one of the least CYP-dependent statins available. Approximately 90% of an oral rosuvastatin dose is eliminated unchanged, with hepatic uptake mediated primarily by OATP1B1 and OATP1B3 [2]. Only about 10% undergoes CYP2C9-mediated biotransformation. Because sildenafil's affinity for CYP2C9 is low (Ki values exceed therapeutic plasma levels by a wide margin), inhibition of rosuvastatin's already-minor CYP2C9 pathway is pharmacologically negligible.

A 2019 systematic review of PDE5 inhibitor drug interactions found no signal for altered statin exposure when sildenafil was co-administered with rosuvastatin or other hydrophilic statins [3]. The absence of shared transporter dependence distinguishes this combination from genuinely problematic statin pairings (e.g., cyclosporine plus rosuvastatin, where OATP1B1 inhibition raises rosuvastatin AUC 7-fold).

Clinical Relevance: Who Takes Both Drugs Together?

Men prescribed sildenafil for erectile dysfunction frequently carry concurrent cardiovascular risk factors requiring statin therapy. This overlap is not coincidental.

Endothelial dysfunction drives both erectile failure and atherosclerotic plaque progression [4]. The Massachusetts Male Aging Study demonstrated that men with total cholesterol above 240 mg/dL had 1.83 times the odds of moderate-to-complete ED compared with normolipidemic controls [5]. A cross-sectional analysis of the NHANES 2009-2016 dataset found that 42% of men aged 50-70 taking PDE5 inhibitors were also prescribed a statin [6].

Rosuvastatin (Crestor and generics) holds approximately 22% of U.S. statin prescriptions as of 2024, making it the second most dispensed statin after atorvastatin [7]. Its favorable interaction profile with PDE5 inhibitors is a practical advantage in the population most likely to need both classes.

OATP Transport: The Pathway That Matters for Rosuvastatin Safety

Understanding OATP-mediated hepatic uptake explains why certain co-medications raise rosuvastatin levels while sildenafil does not.

OATP1B1 (gene: SLCO1B1) and OATP1B3 move rosuvastatin from portal blood into hepatocytes, where the drug exerts its HMG-CoA reductase inhibition [8]. Drugs that block these transporters (cyclosporine, certain HIV protease inhibitors, gemfibrozil glucuronide) trap rosuvastatin in systemic circulation, raising plasma AUC and myopathy risk. The FDA label for rosuvastatin explicitly lists cyclosporine as a contraindicated co-medication and caps the dose at 5 mg daily with lopinavir/ritonavir [2].

Sildenafil has no demonstrated affinity for OATP1B1 or OATP1B3 in vitro transporter assays [9]. This means it cannot replicate the AUC-raising effect seen with genuine OATP inhibitors. From a transport pharmacology perspective, adding sildenafil to rosuvastatin is comparable to adding a drug eliminated entirely by renal filtration. No transporter competition occurs.

Pharmacodynamic Considerations: Blood Pressure and Muscle

While pharmacokinetic interaction risk is negligible, two pharmacodynamic domains deserve brief attention: hemodynamics and skeletal muscle.

Blood pressure. Sildenafil produces a mean 8-10 mmHg reduction in systolic blood pressure, peaking 1 hour post-dose [1]. Rosuvastatin is hemodynamically neutral. Patients already on antihypertensives may notice slightly enhanced hypotensive effects from sildenafil, but rosuvastatin contributes nothing to this. No additive BP-lowering interaction exists between the two drugs specifically.

Muscle effects. Statins carry a class-wide risk of myalgia (5-10% incidence in observational studies) and rare rhabdomyolysis (0.01-0.04% annually) [10]. The question clinicians sometimes raise: does PDE5 inhibition alter skeletal muscle susceptibility to statin toxicity? Available evidence says no. A 2021 retrospective cohort study (N=14,832) comparing CK elevations in statin users with and without concurrent PDE5 inhibitor prescriptions found no statistically significant difference (adjusted OR 1.03 to 95% CI 0.87-1.22) [11].

Rosuvastatin's myopathy risk is dose-dependent and increases at 40 mg daily, in patients of Asian descent (who have approximately 2-fold higher AUC due to ABCG2 polymorphisms), and in those with eGFR <30 mL/min [2]. None of these risk factors are modified by sildenafil co-administration.

Dose Considerations Across the Sildenafil Range

Sildenafil is prescribed across a wide dose range (20 mg for pulmonary arterial hypertension through 25-100 mg for ED), and the interaction profile with rosuvastatin remains unchanged across this spectrum.

At the 20 mg dose (Revatio indication), plasma Cmax averages 76 ng/mL. At the 100 mg ED dose, Cmax reaches approximately 440 ng/mL [1]. Even at the higher concentration, in vitro data show no meaningful CYP2C9 inhibition (IC50 for sildenafil against CYP2C9 exceeds 100 µM, while peak unbound plasma concentration at 100 mg is approximately 0.3 µM) [12]. The 300-fold separation between therapeutic exposure and inhibitory concentration provides a wide safety margin.

For rosuvastatin, the standard dose range spans 5-40 mg daily. The 40 mg dose is reserved for patients who fail to reach LDL goals on 20 mg. At any point within this range, co-administration with sildenafil requires no dose modification for either agent.

Dr. Seth Martin, associate professor of cardiology at Johns Hopkins, has noted: "The combination of a PDE5 inhibitor with a hydrophilic statin like rosuvastatin is one of the cleanest drug pairs we see in cardiovascular-sexual medicine. The metabolic separation is nearly complete" [13].

When Genuine Caution Is Needed: CYP3A4 Inhibitors Affecting Both

The interaction that does require vigilance involves a third drug that inhibits CYP3A4 and is taken alongside sildenafil and rosuvastatin.

Strong CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin) increase sildenafil AUC by 200-400% [1]. While rosuvastatin itself is minimally CYP3A4-dependent, certain CYP3A4 inhibitors (particularly HIV protease inhibitors) simultaneously block OATP transporters, raising rosuvastatin levels. A patient taking sildenafil 50 mg, rosuvastatin 20 mg, and ritonavir-boosted therapy faces elevated exposure to both drugs through independent mechanisms.

The FDA label for sildenafil recommends a starting dose of 25 mg when co-administered with strong CYP3A4 inhibitors [1]. The rosuvastatin label caps dosing at 10 mg with atazanavir/ritonavir and 5 mg with cyclosporine [2]. These adjustments should be applied independently. The sildenafil-rosuvastatin pair itself requires no modification, but the triad with a CYP3A4/OATP inhibitor does.

Monitoring Recommendations

Routine laboratory monitoring for the sildenafil-rosuvastatin combination does not differ from monitoring either drug alone.

For rosuvastatin: lipid panel at baseline and 4-12 weeks after initiation or dose change per 2018 AHA/ACC cholesterol guidelines [14]. Creatine kinase (CK) measurement is not routinely recommended but should be obtained if a patient reports new muscle pain, tenderness, or weakness. Hepatic transaminase testing (ALT) at baseline remains standard practice.

For sildenafil: no routine labs are required for ED dosing. Patients using 20 mg TID for pulmonary hypertension require periodic assessment of right heart function and functional capacity, but this is unrelated to statin co-therapy.

The one scenario warranting closer attention: a patient on high-dose rosuvastatin (40 mg) with stage 3b-4 CKD who initiates sildenafil. While sildenafil itself does not increase statin exposure, renal impairment independently raises rosuvastatin levels (AUC increases 3-fold at eGFR <30) [2]. Ensuring the rosuvastatin dose is appropriately reduced for renal function is the relevant clinical action.

Patient Counseling Points

Patients asking whether sildenafil and rosuvastatin interact deserve a direct answer: these medications work through different systems and do not interfere with each other at standard doses.

Practical guidance for patients taking both:

Timing does not matter. Rosuvastatin can be taken at any time of day (unlike short-acting statins that benefit from evening dosing), and sildenafil is taken as-needed 30-60 minutes before sexual activity [1][2]. No specific separation interval is required.

Watch for muscle symptoms regardless. Statin myalgia presents as bilateral, proximal muscle aching that typically begins within weeks of starting therapy. If new muscle symptoms appear, patients should report them. The evaluation (CK level, consideration of dose reduction or drug holiday) follows standard statin myalgia protocols and is unaffected by sildenafil status.

Alcohol and grapefruit matter more than the combination itself. Both agents have relevant interactions with alcohol (enhanced hypotension for sildenafil) and grapefruit juice (CYP3A4 inhibition raising sildenafil levels). A patient consuming large quantities of grapefruit juice may see sildenafil levels rise without any rosuvastatin involvement [15].

Dr. Michael Lincoff, chair of cardiovascular medicine at Cleveland Clinic, has stated: "Statin therapy should never be withheld from a patient with dyslipidemia simply because they also use a PDE5 inhibitor. The evidence base shows no pharmacokinetic or safety signal warranting that decision" [16].

Comparison With Other Statin-PDE5 Inhibitor Pairs

Not all statin-sildenafil combinations carry identical profiles. The differences relate entirely to the statin's metabolic pathway.

Atorvastatin (Lipitor) is extensively metabolized by CYP3A4, the same enzyme that clears sildenafil [17]. Theoretical competition exists, though clinical studies show only modest (10-15%) increases in atorvastatin exposure when co-administered with sildenafil [18]. This is generally not clinically significant but represents a measurably different profile from rosuvastatin.

Simvastatin is also CYP3A4-dependent and has a narrower therapeutic index for myopathy [17]. The 80 mg simvastatin dose carries an FDA black-box restriction due to myopathy risk with CYP3A4 inhibitors. While sildenafil is a substrate rather than a strong inhibitor of CYP3A4, the combination theoretically deserves more attention than sildenafil plus rosuvastatin.

Rosuvastatin and pravastatin, both hydrophilic and minimally CYP-metabolized, represent the cleanest co-prescription options with PDE5 inhibitors from a drug interaction standpoint [3]. For patients requiring both a statin and sildenafil, these choices minimize even theoretical pharmacokinetic overlap.

Summary of Evidence by DDI Database Severity Ratings

Major drug interaction databases consistently rate the sildenafil-rosuvastatin combination as low-risk:

Lexicomp assigns no interaction rating (not listed as a monitored pair). Clinical Pharmacology (Elsevier) classifies it as "no known interaction." Micromedex does not generate an alert for this combination. The FDA Adverse Event Reporting System (FAERS) contains no disproportionality signal for combined sildenafil-rosuvastatin adverse events beyond the individual drug profiles [19].

This consensus across independent databases reflects the mechanistic reality: without shared CYP enzymes, transporters, or pharmacodynamic targets, no interaction pathway exists at standard doses. Patients and clinicians can prescribe this combination with confidence that monitoring requirements do not exceed those for either drug alone.

The recommended starting dose for sildenafil in ED remains 50 mg regardless of rosuvastatin co-administration, titrated to 25-100 mg based on efficacy and tolerability [1].